Skip to content

Study · Not a test of the peptide alone · 2014

9 results

Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women.

Norman C, Rollene NL, Erickson D, Miles JM, Bowers CY, Veldhuis JD

European journal of endocrinology29 Nov 2013Cited by 8 (Europe PMC)

PMID24114435 (opens in a new tab)PMCIDPMC3892701 (opens in a new tab)DOI10.1530/eje-13-0733 (opens in a new tab)PepBankPUB-24114435
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In healthy postmenopausal women, estradiol versus placebo augmented mean 13-h GH concentrations during GHRH, somatostatin and GHRP2 infusion protocols.

    In plain wordsIn postmenopausal women, estradiol raised average growth hormone levels more than placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseMean 13-h GH concentration
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    E₂ vs placebo supplementation: i) augmented mean (13-h) GH concentrations (P=0.023)
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In healthy postmenopausal women, estradiol versus placebo augmented GHRH-induced pulsatile GH secretion over the first 3 h.

    In plain wordsIn postmenopausal women, estradiol boosted GHRH-driven growth hormone pulses in the first hours more than placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRH-induced pulsatile GH secretion over the first 3 h
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    E₂ vs placebo supplementation: i) augmented mean (13-h) GH concentrations (P=0.023), GHRH-induced pulsatile GH secretion over the first 3 h (P=0.0085)
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In healthy postmenopausal women, the estradiol versus placebo difference in pulsatile GH secretion over the next 10 h had P=0.054.

    In plain wordsIn postmenopausal women, estradiol did not clearly change later growth hormone pulses compared with placebo.

    Peptide
    GHRP-2
    Outcome
    No significant changePulsatile GH secretion over the next 10 h
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    E₂ vs placebo supplementation: i) augmented mean (13-h) GH concentrations (P=0.023), GHRH-induced pulsatile GH secretion over the first 3 h (P=0.0085) and pulsatile GH secretion over the next 10 h (P=0.054)
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 04HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In healthy postmenopausal women, estradiol versus placebo increased GHRP-modulated GH approximate entropy.

    In plain wordsIn postmenopausal women, estradiol made growth hormone release less regular during GHRP stimulation than placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRP-modulated GH approximate entropy
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    ii) increased GHRP-modulated (P=0.022) and SS-modulated (P<0.001)
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  5. 05HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In healthy postmenopausal women, estradiol versus placebo increased somatostatin-modulated GH approximate entropy.

    In plain wordsIn postmenopausal women, estradiol made growth hormone release less regular during somatostatin infusion than placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseSS-modulated GH approximate entropy
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    ii) increased GHRP-modulated (P=0.022) and SS-modulated (P<0.001)
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  6. 06HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In healthy postmenopausal women, estradiol versus placebo did not amplify GHRH/GHRP synergy during pulsatile GH secretion.

    In plain wordsIn postmenopausal women, estradiol did not strengthen the joint effect of GHRH and GHRP on growth hormone.

    Peptide
    GHRP-2
    Outcome
    No significant changeGHRH/GHRP synergy on pulsatile GH secretion
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    and iii) did not amplify GHRH/GHRP synergy during pulsatile GH secretion.
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  7. 07HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In postmenopausal women, estradiol concentrations were positively correlated with GH secretion during GHRP2 infusion.

    In plain wordsIn postmenopausal women, higher estradiol went with more growth hormone release during GHRP2 infusion.

    Peptide
    GHRP-2
    Outcome
    IncreaseCorrelation of estradiol with GH secretion during GHRP2 infusion
    Study

    n = 24

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    By linear regression, E₂ concentrations were found to be positively correlated with GH secretion during GHRP2 infusion (P=0.022)
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  8. 08HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In postmenopausal women, BMI was negatively correlated with GH secretion during GHRH and combined GHRH/GHRP stimulation.

    In plain wordsIn postmenopausal women, a higher BMI went with less growth hormone release during GHRH and GHRH plus GHRP.

    Peptide
    GHRP-2
    Outcome
    DecreaseCorrelation of BMI with GH secretion during GHRH and combined GHRH/GHRP stimulation
    Study

    n = 24

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    BMI was found to be negatively correlated with GH secretion during GHRH (P=0.006) and combined GHRH/GHRP (P=0.015) stimulation.
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  9. 09HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    Estradiol and BMI jointly determined triple stimulation of GH secretion after saline and after pulsatile GHRH infusions.

    In plain wordsEstradiol and BMI together explained part of the growth hormone response to combined stimulation.

    Peptide
    GHRP-2
    Outcome
    Not applicableJoint estradiol and BMI determination of triple stimulation of GH secretion
    Study

    n = 24

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    E₂ and BMI jointly determined triple (combined l-arginine, GHRH, and GHRP2) stimulation of GH secretion after saline (R²=0.44 and P=0.003) and pulsatile GHRH (R²=0.39 and P=0.013) infusions.
    1 context sentence
    Summary · context
    The design comprised double-blind randomized prospective administration of transdermal E₂ vs placebo to healthy postmenopausal women (n=24) followed by pulsatile GHRH or SS infusions for 13 h overnight with or without continuous GHRP2 stimulation.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.